- Stocks
- Pharma & Healthcare
- Syngene International
Syngene International share price
NSE: SYNGENEPharma & HealthcareDiagnostics & Research
Syngene International at a glance
Syngene International (NSE: SYNGENE) closed at ₹370.75 on 22 Oct 2026, down 1.12% on the day. With a market capitalisation of ₹14,966 Cr, it ranks 424th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 47× trailing earnings, against a return on equity of 6.5% in FY26. Over the past year the share price has fallen 40.8%. Its 52-week range is ₹344.45 (9 Oct 2026) to ₹678.95 (7 Jan 2026); the last close is 45.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹736 Cr (−15.8% year on year) and net profit −₹9 Cr (−110.4%), on a consolidated basis. Promoters held 52.59% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹14,966 CrRank 424 on NSE
- P/E (trailing)
- 47×
- Price to book
- 3.25×FY26
- EPS (TTM)
- ₹5.50to Q1 FY27
- ROE
- 6.5%FY26
- ROCE
- 9.7%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 8.5%FY26
- Book value / share
- ₹120.11FY26
- Dividend payout
- 15.9%FY26
- 52-week high
- ₹678.957 Jan 2026
- 52-week low
- ₹344.459 Oct 2026
- 1-year return
- −40.8%
- RSI (14-day)
- 46.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.12% | −5.1% | −3.8% | −8.8% | −40.8% |
Syngene International quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹891 Cr | ₹944 Cr | ₹1,018 Cr | ₹875 Cr | ₹911 Cr | ₹917 Cr | ₹1,037 Cr | ₹736 Cr |
| Revenue YoY | −2.1% | +10.6% | +11.0% | +10.7% | +2.2% | −2.8% | +1.8% | −15.8% |
| Net profit | ₹106 Cr | ₹131 Cr | ₹183 Cr | ₹87 Cr | ₹67 Cr | ₹15 Cr | ₹148 Cr | −₹9 Cr |
| Net profit YoY | −8.9% | +17.6% | −2.8% | +14.5% | −36.8% | −88.6% | −19.3% | −110.4% |
| Net margin | 11.9% | 13.9% | 18.0% | 9.9% | 7.4% | 1.6% | 14.3% | −1.2% |
| EPS | ₹2.64 | ₹3.27 | ₹4.56 | ₹2.16 | ₹1.67 | ₹0.37 | ₹3.68 | −₹0.22 |
Syngene International financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,184 Cr | ₹2,604 Cr | ₹3,193 Cr | ₹3,489 Cr | ₹3,642 Cr | ₹3,739 Cr |
| Operating profit | ₹434 Cr | ₹515 Cr | ₹594 Cr | ₹632 Cr | ₹628 Cr | ₹488 Cr |
| Net profit | ₹405 Cr | ₹396 Cr | ₹464 Cr | ₹510 Cr | ₹496 Cr | ₹317 Cr |
| EPS (₹) | ₹10.00 | ₹10.00 | ₹12.00 | ₹13.00 | ₹12.00 | ₹8.00 |
| Cash from operations | ₹701 Cr | ₹581 Cr | ₹824 Cr | ₹1,042 Cr | ₹1,168 Cr | ₹915 Cr |
| Total debt | ₹512 Cr | ₹532 Cr | ₹489 Cr | ₹100 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹2,821 Cr | ₹3,298 Cr | ₹3,618 Cr | ₹4,258 Cr | ₹4,727 Cr | ₹4,839 Cr |
Syngene International shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 52.74% | 52.68% | 52.68% | 52.68% | 52.68% | 52.59% |
| Foreign institutions | 19.47% | 16.50% | 16.31% | 14.96% | 13.90% | 11.82% |
| Domestic institutions | 21.50% | 24.05% | 24.62% | 25.84% | 26.44% | 28.02% |
| Non-institutions | 6.00% | 6.45% | 6.08% | 6.22% | 6.69% | 7.14% |
Syngene International vs peers
The listed Pharma & Healthcare companies nearest to Syngene International by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ALIVUSAlivus Life Sciences | ₹1,272.00 | +0.82% | +37.5% | ₹15,612 Cr | 27.7 | — |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −0.41% | −14.0% | ₹15,430 Cr | 22.9 | — |
| ASTRAZENAstraZeneca Pharma India | ₹6,056.00 | −0.38% | −33.5% | ₹15,140 Cr | 80.9 | — |
| POLYMEDPoly Medicure | ₹1,479.10 | +1.31% | −20.5% | ₹14,992 Cr | 46.7 | — |
| SYNGENESyngene International | ₹370.75 | −1.12% | −40.8% | ₹14,966 Cr | 47 | — |
| JUBLPHARMAJubilant Pharmova | ₹930.80 | −0.02% | −13.4% | ₹14,826 Cr | 37.1 | — |
| AGARWALEYEDr. Agarwal's Health Care | ₹459.10 | −1.51% | −10.7% | ₹14,553 Cr | — | — |
Ask anything about Syngene International
Pivot answers on the live chart with evidence you can check, and tests strategies against SYNGENE's own history. Try: “Why has SYNGENE moved over the last three months?” · “Backtest a 50-day moving-average crossover on SYNGENE over five years” · “Compare SYNGENE with ALIVUS on margins and valuation”
Frequently asked questions about Syngene International
What is the share price of Syngene International today?
Syngene International (NSE: SYNGENE) last closed at ₹370.75 on 22 Oct 2026. Its 52-week high is ₹678.95 and its 52-week low is ₹344.45.
What is the market cap of Syngene International?
Syngene International's market capitalisation is ₹14,966 Cr (₹14,966 Cr) at the 22 Oct 2026 close, ranking 424th among the NSE companies Pivot tracks.
What is the P/E ratio of Syngene International?
Syngene International trades at a trailing P/E of 47. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 37.1.
What is the ROE and ROCE of Syngene International?
Return on equity was 6.5% in FY26 and return on capital employed was 9.7% in FY26 (consolidated figures).
Is Syngene International a debt-free company?
Syngene International is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Syngene International's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Syngene International reported revenue of ₹736 Cr, −15.8% year on year, and net profit of −₹9 Cr, −110.4% year on year.
How has Syngene International stock performed over the last year?
Syngene International's share price has fallen 40.8% over the past year, −8.8% over three months and −3.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Syngene International?
As of 30 Jun 2026: promoters 52.59%, foreign institutions 11.82%, domestic institutions 28.02%, non-institutions 7.14%.
Who are Syngene International's competitors?
The listed Pharma & Healthcare companies closest to Syngene International by market cap are Alivus Life Sciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Poly Medicure, Jubilant Pharmova and Dr. Agarwal's Health Care.
Is Syngene International a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Syngene International's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SYNGENE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text